	US 12,065,487 B2
	Antigen-binding molecules and uses thereof
Samantha J. Busfield, Victoria (AU); and Matthew J. Wilson, Philadelphia, PA (US)
Assigned to Scout Bio, Inc., Philadelphia, PA (US)
Filed by Scout Bio, Inc., Philadelphia, PA (US)
Filed on Jun. 21, 2023, as Appl. No. 18/339,094.
Application 18/339,094 is a continuation of application No. PCT/US2022/075788, filed on Aug. 31, 2022.
Claims priority of provisional application 63/239,054, filed on Aug. 31, 2021.
Prior Publication US 2023/0365670 A1, Nov. 16, 2023
Int. Cl. C07K 16/22 (2006.01); A61P 25/00 (2006.01); C12N 15/86 (2006.01)

CPC C07K 16/22 (2013.01) [A61P 25/00 (2018.01); C12N 15/86 (2013.01); C07K 2317/565 (2013.01); C12N 2750/14143 (2013.01)]

4 Claims

1. An antibody or an antigen-binding fragment thereof that specifically binds to nerve growth factor (NGF), wherein the antibody or an antigen-binding fragment thereof comprises an immunoglobulin heavy chain variable domain (VH) and an immunoglobulin light chain variable domain (VL), wherein the VH comprises a complementarity determining region 1 (VH CDR1) comprising the amino acid sequence of SEQ ID NO: 1, a VH CDR2 comprising the amino acid sequence of SEQ ID NO: 2 and a VH CDR3 comprising the amino acid sequence of SEQ ID NO: 3; and wherein the VL comprises a complementarity determining region 1 (VL CDR1) comprising the amino acid sequence of SEQ ID NO: 4, a VL CDR2 comprising the amino acid sequence of SEQ ID NO: 5, and a VL CDR3 comprising the amino acid sequence of SEQ ID NO: 6.